PROGRAM

Conference

Check

List
Business & Development
May 9 (Thu) 09:50~12:05, Rm.308
Session 5. Bio‧Pharmaceutical Global Open Innovation Cooperation and Activation Strategy Part.1
Cases of Bio‧Pharmaceutical Open Innovation Collaboration in the Global Market
   This session aims to present recent global open innovation collaboration models and share key success stories to provide direction for the Korean pharmaceutical industry to create more success stories through global open innovation. This session is divided into Part 1 and Part 2, Part 1 thoroughly explores the business development strategies of global pharmaceutical companies and shares insightful examples of open innovation collaborations.
Co-organized By KRIPA(한국글로벌의약산업협회)
  • Opening
  • 09 : 50 ~ 10 : 00
  • BeiGene’s Global Expansion and its R&D strategy in BTKi to begin
  • Adam RoachVice President Head of Asia Pacific, Corporate & Executive, BeiGene Australia Pty Ltd
  • 10 : 00 ~ 10 : 15
  • BeiGene’s R&D Strategy and pipeline in Solid Tumor
  • Mark LanasaSVP, Chief Medical Officer, Solid Tumors, R&D | Clinical Development, BeiGene Global
  • 10 : 15 ~ 10 : 35
  • BeiGene’s Approach to Partnering
  • Evan GoldbergVP, Business Development, APAC and Emerging Markets, Business Development, BeiGene Global | APAC & Emerging Markets
  • 10 : 35 ~ 10 : 50
  • Prioritizing Partnerships to Get ahead of Disease
  • Sang-eun LeeDirector, Business Development, R&D, GSK
  • 10 : 55 ~ 11 : 25
  • The Application of Human Preclinical Tools to Support Drug Design and Regulatory Submission
  • Noel SmithHead of Immunology, Early Development Services, Lonza Biologics
  • 11 : 30 ~ 12 : 00
  • Closing
  • 12 : 00 ~ 12 : 05
 

BIO KOREA 2024 PARTNERS

BIO KOREA 2024 SPONSORS